Incyte Corporation (INCY)

[surf1944]

1:44AM Incyte Pharma: Data from a Ph. I/II study suggest that INCB7839 in combination with trastuzumab may improve clinical response rtes in HER2 positive patients with advanced metastatic disease (INCY) 8.02 : Co announces positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer. The results suggest that, when compared to a historical control study of trastuzumab as monotherapy, INCB7839 in combination with trastuzumab provided improvements in time to progression and response rate in patients with HER2 positive metastatic breast cancer. These improved outcomes were achieved despite the presence of more advanced disease in the study population when compared to the historical control. The improved response rate observed in this study are thought to result from an increased response in the p95HER2 positive subpopulation.